Figure 3 from ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance
Year: 2025
Type: other
Abstract: ATM inhibition reverses the myofibroblast CAF phenotype and inhibits function. A–C, Western blotting of HNSCC (A) and NSCLC (B) CAF treated with KU55933 for 7 days and their quantification (C). D, qRT-PCR of CAF (NSCLC, n = 1; HNSCC, n = 2) stably expressing either shCTR or shATM (ntr = 3). E, Collagen gel contraction assay and measurement of gel area of shCTR or shATM HNSCC and NSCLC CAF (left, representative gel images; ntr = 2). F and G, Transwell invasion assays of H441 (F) or 5PT (G) cells toward CAF-conditioned media generated from NSCLC (nbr = 3; ntr = 3–5; F) and HNSCC (nbr = 8; ntr = 2–4; G) treated as in A (means are shown and two-way ANOVA is used and refers to the control). Heteroscedastic Student t test is shown throughout the figure and refers to the control unless otherwise stated. *, P ≤ 0.05; **, P ≤ 0.01.
Authors: Massimiliano Mellone, Klaudia Piotrowska, Giulia Venturi, Lija James, Aleksandra Bzura, Maria A. Lopez, Sonya James, Chuan Wang, Matthew J. Ellis, Christopher J. Hanley, Josephine F. Buckingham, Kerry L. Cox, Gareth Hughes, Viia Valge-Archer, Emma V. King, Stephen A. Beers, Vincent Jaquet, George D.D. Jones, Natalia Savelyeva, Emre Sayan, Jason L. Parsons, Stephen Durant, Gareth J. Thomas
Language: English
Topic: Cancer Cells and Metastasis
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416587729